Development of Medications for the Treatment of Opiate and Cocaine Addictions

Issues for the Government and Private Sector

Häftad, Engelska, 1995

AvInstitute of Medicine,Committee to Study Medication Development and Research at the National Institute on Drug Abuse,Laurence E. Earley,Catharyn T. Liverman,Carolyn E. Fulco

1 829 kr

Tillfälligt slut

Pharmacotherapy, as a means of treating drug addiction in combination with other treatment modalities, has received too little attention from the research community, the pharmaceutical industry, public health officials, and the federal government. Medications to combat drug addiction could have an enormous impact on the medical consequences and socioeconomic problems associated with drug abuse, both for drug-dependent individuals and for American society as a whole. This book examines the current environment for and obstacles to the development of anti-addiction medications, specifically those for treating opiate and cocaine addictions, and proposes incentives for the pharmaceutical industry that would help overcome those obstacles and accelerate the development of anti-addiction medications.

Produktinformation

Utgivningsdatum1995-01-20
Mått152 x 229 x 25 mm
Vikt440 g
FormatHäftad
SpråkEngelska
Antal sidor272
FörlagNational Academies Press
ISBN9780309052443

Tillhör följande kategorier

Beteendeteori inom Psykologi och pedagogik
Farmakologi inom Medicin
Missbruk inom Medicin

1 Front Matter; 2 Executive Summary; 3 1 Introduction; 4 2 Overview of the State of Scientific Knowledge Concerning Drug Addiction; 5 3 Assessment of the Medications Development Division; 6 4 Treatment Setting and Effectiveness; 7 5 Treatment Financing and Trends in Health Insurance; 8 6 Training and Education; 9 7 Federal Laws and Regulations; 10 8 State Laws and Regulations; 11 9 Market Obstacles and Creating Incentives; 12 Appendix A: Acknowledgments; 13 Appendix B: Organization and Mission Statements of NIDA's Medications Development Division and Its Branches; 14 Appendix C: Diagnostic Criteria for Psychoactive Substance Dependence; 15 Appendix D: Survey of Pharmaceutical Companies; 16 Appendix E: Model Federal Programs in Pharmaceutical R&D; 17 Appendix F: Workshop Agenda and Participants; 18 Appendix G: Health Care Reform Legislation; 19 Appendix H: Acronyms

Mer från samma författare

To Err Is Human

Institute of Medicine, Committee on Quality of Health Care in America, Molla S. Donaldson, Janet M. Corrigan, Linda T. Kohn

Häftad

659 kr

From Neurons to Neighborhoods

National Research Council, Division of Behavioral and Social Sciences and Education, Institute of Medicine, and Families Board on Children, Youth, Steve Olson

Häftad

379 kr

Health of Lesbian, Gay, Bisexual, and Transgender People

Institute of Medicine, Board on the Health of Select Populations, and Transgender Health Issues and Research Gaps and Opportunities Committee on Lesbian, Gay, Bisexual

Häftad

729 kr

Bereavement

Institute of Medicine, Committee for the Study of Health Consequences of the Stress of Bereavement

Häftad

2 619 kr

New Vaccine Development

Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health

Häftad

2 549 kr

Social and Built Environment in an Older Society

Institute of Medicine, Committee on an Aging Society

Häftad

2 289 kr

Physician Staffing for the VA

Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb

Häftad

1 659 kr